Clinical Pipeline

Click the program to learn more

Phase I
Phase II
Phase III

Metastatic Melanoma

Metastatic Melanoma

Phase II study to assess the safety and efficacy of multiple treatment cycles of ImmunoPulse® IL-12 monotherapy in patients with in-transit cutaneous and subcutaneous metastatic melanoma. Patients are currently being enrolled into an extension arm of the study to evaluate a new six-week treatment cycle.

Combination Study

Melanoma Combination

Phase II study to evaluate the safety and efficacy of ImmunoPulse® IL-12 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with advanced metastatic melanoma.

Triple Negative
Breast Cancer

Breast Cancer

Phase II pilot study to evaluate the ability of ImmunoPulse® IL-12 to promote an immunogenic tumor microenvironment in advanced recurrent triple negative breast cancer (TNBC).

Solid Tumors

Solid Tumors

Orange = Monotherapy with IL-12 | Green = Combination Therapy | Blue = New Combination Molecule Candidate

Learn more about our current clinical trials.LEARN MORE

Real Time Web Analytics